r/TenayaTherapeutics

Piper Sandler reiterated its Overweight rating and $40.00 price target on Tenaya Therapeutics (NASDAQ: TNYA), arguing that the market is overlooking a key potential value driver: TN-301.

The analysts note that the Street currently assigns no value to TNYA for TN-301, an in-house small molecule HDAC6 inhibitor they see as a potentially major opportunity across cardiovascular and orphan indications. They frame the space as under-exploited — only 5 pan-HDAC inhibitors are approved versus 6 HDAC6-specific inhibitors in development — and point to validating deal activity, notably Novartis' (NVS) up-to $1.3B licensing agreement for PKN605, an HDAC6 inhibitor in Phase 2 for atrial fibrillation (AF).

Tenaya is positioned ahead on this front: TN-301 is Phase 2-ready across several indications, with a 2H26 update expected to clarify indication selection and timelines. Piper's deep dive covers TN-301's Phase 1 data in healthy volunteers (HVs) and preclinical work (5 in-vivo, 3 ex-vivo) spanning indications such as HFpEF and DMD.

The firm views the setup as an opportune buying opportunity, casting the 2H26 update as a key inflection point that could solidify TN-301's "pipeline-in-a-pill" value proposition.

Source: https://www.investing.com/news/pro/piper-sandler-maintains-tenaya-therapeutics-at-overweight-with-a-price-target-of-40000-4776752

Tenaya is finalizing a shift to an asset-light operational model. By taking a one-time loss of roughly $2 million to shed a long-term lease obligation, they are reducing future cash burn while relying on existing inventory to sustain their current gene therapy pipeline

Some of my thoughts

Tenaya could possibly own entire HFpEF & HFrEF heart failure spectrum. A strategic pincer of the whole cardiology industry managing and restoring both systolic and diastolic function.
i.e (TN-301 & TN-101) phase 2 and IND phase respectively.

Does anyone else believe that this company is an industry blind spot?

Also what do we think of tn-301 pipeline in a pill? Cardiac, pulmonary, metabolic etc. Massive potential with 3000 fold selectivity.
I heard someone describe it as the fountain of youth.😄 Sensational.

GLTA

Tenaya Therapeutics (NASDAQ:TNYA) appointed Eric Hyllengren as Chief Financial Officer effective July 13, 2026. He will lead financial strategy, capital allocation, investor relations and corporate development.

Cash Compensation: An annual base salary of $490,000, plus eligibility for a 40% target annual bonus.
​Equity Options: An inducement grant of options to purchase 1,650,000 shares of Tenaya's common stock.
​Vesting Schedule: The options have a 10-year term and vest over four years (25% after the first year, and 1/48th monthly thereafter).
​Severance: Eligibility for the company's Executive Change in Control and Severance Plan at the Tier 2 level.

​

​Right now, the tight margin between the $0.70 strike price and the actual trading price creates a strong mechanical and psychological gravitational pull on the stock. Here is what is happening behind the scenes leading up to June 30th:

​Arbitrage and Selling Pressure: Warrant holders looking to lock in a guaranteed profit will exercise their warrants at $0.70 and immediately sell the resulting common stock on the open market at $0.73. This creates a natural "ceiling" on the stock price because any upward momentum is met with immediate selling volume from players scraping that tiny spread.

​Hedging Mechanics: Institutional investors often short the underlying stock against their long warrant positions to lock in gains early. This mechanical shorting adds temporary downward pressure.

​The Overhang Discount: The market dislikes a looming supply shock. Knowing that a fresh block of cheap shares could suddenly expand the public float acts as a damper on new institutional buyers, who often choose to sit on the sidelines until the expiration date passes.

​What Normally Happens After Expiration?

​Once the June 30th deadline hits at 5:00 PM ET, the artificial trading dynamics vanish. The aftermath depends entirely on whether the stock finishes above or below the strike price